Updated on 24 July 2013
Led by the strong onset of monsoons all across the country, acute therapies grew almost at par with the chronic segment. Acute therapies contributed 71 percent to total with growth of 8.8 percent and chronic therapies contributed 29 percent with growth of nine percent.
The IMS market Prognosis report forecasted that the market will recover over the next few months, as issues around market regulations clear out and register a FY 2013 growth between 11-13 percent.
The pharmaceutical market for the period MAT June 2013, improved by 10 percent. Abbott remained on top position followed by Cipla, Sun Pharmaceutical, GlaxoSmithKline and Zydus Cadila respectively.